Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer

Journal of Clinical Oncology

Volumn 26, Issue 20, 2008, Pages 3317-3323

  Storniolo, Anna Maria ^a   Pegram, Mark D ^b   Overmoyer, Beth ^b   Silverman, Paula ^b   Peacock, Nancy W ^b   Jones, Suzanne F ^b   Loftiss, Jill ^b   Arya, Nikita ^b   Koch, Kevin M ^b   Paul, Elaine ^b   Pandite, Lini ^b   Fleming, Ronald A ^b   Lebowitz, Peter F ^b   Ho, Peter T C ^b   Burris III, Howard A ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; AGED; BREAST TUMOR; CANCER INVASION; DRUG ADMINISTRATION; FOLLOW UP; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; MAXIMUM TOLERATED DOSE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; QUINAZOLINES; RECEPTOR, ERBB-2; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 49149084837     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.5202     Document Type: Article

References (23)

1. Agrawal A, Gutteridge E, Gee JMW, et al: Overview of tyrosine kinase inhibitors in clinical breast cancer. Endo Rel Cancer 12:S135-S144, 2005
2. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
3. Revillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34:791-808, 1998
4. Alroy I, Yarden Y: Biochemistry of HER2 oncogenesis in breast cancer. Breast Dis 11:31-48, 2000
5. Rusnak DW, Lackey K, Affleck K, et al: The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1:85-94, 2001
6. Gaul MD, Guo Y, Affleck K, et al: Discovery and biological evaluation of potent dual erbB-2/EGFR tyrosine kinase inhibitors: 6-thiazolyquinazolines. Bioorgan Med Chem Lett 13:637-640, 2003
7. Wood ER, Truesdale AT, McDonald OB, et al: A unique structure for epidermal growth factor receptor bound to GW572016 (lapatinib): Relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64:6652-6659, 2004
8. Xia W, Mullin RJ, Keith BR, et al: Anti-tumor activity of GW572016: A dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21:6255-6263, 2002
9. Gee J: Chaperone-mediated destruction of erbB2: Relevance to tyrosine kinase inhibitors. Breast Cancer Res 4:205-206, 2002
10. Konecny G, Pegram MD, Venkatesan N, et al: Activity of the dual kinase inhibitor lapatinib against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66:1630-1639, 2006
11. Hsieh S, Tobien T, Koch K, et al: Increasing throughput of parallel on-line extraction liquid chromatography/ electrospray ionization tandem mass spectrometry system for GLP quantitative bioanalysis in drug development. Rapid Commun Mass Spectrom 18:285-292, 2004
12. Cobleigh MA, Vogel CL, Tripathy D, et al: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648, 1999
13. Vogel CL, Cobleigh MA, Tripathy D, et al: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726, 2002
14. Perez EA, Byrne JA: Results of an analysis of cardiac function in 3127 patients treated with lapatinib. J Clin Oncol 24:23s, 2006 (suppl; abstr 583)
15. Carter P, Presta L, Gorman CM, et al: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A 89:4285-4289, 1992
16. Lin YL, Clinton GM: A soluble protein related to the HER-2 proto-oncogene product is released from human breast carcinoma cells. Oncogene 6:639-643, 1991
17. Pupa SM, Menard S, Morelli D, et al: The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8:2917-2923, 1993
18. 2-terminally truncated Her-2/neu protein: Relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 58:5123-5129, 1998
19. Xia W, Liu LH, Ho P, et al: Truncated erbB2 receptor (p95erbB2) is regulated by heregulin through heterodimer formation with erbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 23:646-653, 2004
20. Saez R, Molina M, Ramsey EE, et al: P95HER-2 predicts worse outcome in patients with HER-2 positive breast cancer. Clin Cancer Res 12:424-430, 2006
21. 2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 8:347-353, 2002
22. Pusztai L, Esteva FJ: Continued use of trastuzumab (Herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer. Cancer Invest 24:187-191, 2006
23. Moy B, Goss PE: Lapatinib: Current status and future directions in breast cancer. Oncologist 11:1047-1057, 2006